Investigating how Fas/CD95 affects immune response in triple negative breast cancer
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
This study is looking at how a protein called Fas/CD95 affects the immune system's ability to fight triple negative breast cancer, with the goal of finding new treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10872213 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Fas/CD95, a protein involved in cell death, in triple negative breast cancer (TNBC). It aims to explore how Fas/CD95 may suppress the immune response against tumors, particularly by recruiting immune cells that inhibit tumor-fighting natural killer (NK) cells. The study utilizes genetically engineered mouse models to observe the effects of Fas expression on tumor growth and immune cell interactions. By uncovering these mechanisms, the research seeks to identify potential new therapeutic targets for TNBC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with non-breast cancers or those with other subtypes of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the immune response against triple negative breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting immune suppression in cancer, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Peter, Marcus E. — Northwestern University at Chicago
- Study coordinator: Peter, Marcus E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.